Wednesday's Health Winners and Losers
Shares of adult stem cell company Osiris Therapeutics (OSIR) took a hit on a downgrade from a Jefferies & Co. analyst Wednesday.
"While we continue to believe OSIR provides long-term potential for its adult stem cell technology, we step to the sidelines for a better entry point," said biotech analyst Eun Yang, who downgraded the stock to hold from buy. Shares sank 8% to $23.29.
Under the deal, Quest will assist Ciphergen in the development of the blood-based test. The companies previously agreed to jointly develop a test to detect ovarian tumors.Biotechnology company Exelixis (EXEL) said it will get $40 million in upfront and milestone payments in a cancer drug development deal with Genentech (DNA). Under the deal, Exelixis will develop the drug, dubbed XL518, after which Genentech has the option to further develop the drug for additional payments and development costs. Exelixis shares gained 4.6% to $9.41, and Genentech's shares were up 0.9% to $81.86. Shares of Cytokinetics (CYTK) soared after its partner Amgen (AMGN) set plans to work on a new heart failure treatment. Amgen will pay Cytokinetics an upfront payment of $42 million for licensing and access to its technology. It will purchase 3.5 million Cytokinetics shares at $9.47 a share. Cytokinetics shares gained 13% to $8.45, and Amgen's shares were up 0.6% to $68.73.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV